View Item 

Show simple item record

Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2
dc.contributor.authorSeshadri, Sudha
dc.contributor.authorBeiser, Alexa
dc.contributor.authorAu, Rhoda
dc.contributor.authorWolf, Philip A.
dc.contributor.authorEvans, Denis A.
dc.contributor.authorWilson, Robert S.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorKnopman, David S.
dc.contributor.authorRocca, Walter A.
dc.contributor.authorKawas, Claudia H.
dc.contributor.authorCorrada, Maria M.
dc.contributor.authorPlassman, Brenda L.
dc.contributor.authorLanga, Kenneth M.
dc.contributor.authorChui, Helena C.
dc.date.accessioned2020-01-13T15:05:11Z
dc.date.available2020-01-13T15:05:11Z
dc.date.issued2011-01
dc.identifier.citationSeshadri, Sudha; Beiser, Alexa; Au, Rhoda; Wolf, Philip A.; Evans, Denis A.; Wilson, Robert S.; Petersen, Ronald C.; Knopman, David S.; Rocca, Walter A.; Kawas, Claudia H.; Corrada, Maria M.; Plassman, Brenda L.; Langa, Kenneth M.; Chui, Helena C. (2011). "Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2." Alzheimer’s & Dementia 7(1): 35-52.
dc.identifier.issn1552-5260
dc.identifier.issn1552-5279
dc.identifier.urihttps://hdl.handle.net/2027.42/152578
dc.publisherAmerican Psychiatric Association
dc.publisherWiley Periodicals, Inc.
dc.subject.otherAlzheimer’s disease
dc.subject.otherIncidence
dc.subject.otherPrevalence
dc.subject.otherPopulation‐based
dc.subject.otherDiagnostic criteria
dc.subject.otherCognitive impairment not dementia
dc.subject.otherMild cognitive impairment
dc.subject.otherDementia
dc.titleOperationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 2
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurology and Neurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/152578/1/alzjjalz201012002.pdf
dc.identifier.doi10.1016/j.jalz.2010.12.002
dc.identifier.sourceAlzheimer’s & Dementia
dc.identifier.citedreferenceRS Wilson, LA Beckett, DA Bennett, MS Albert, DA Evans. Change in cognitive function in older persons from a community population: relation to age and Alzheimer disease. Arch Neurol. 56: 1999; 1274 – 1279
dc.identifier.citedreferenceR Gijsen, N Hoeymans, FG Schellevis, D Ruwaard, WA Satariano, GA van den Bos. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 54: 2001; 661 – 674
dc.identifier.citedreferenceKM Langa, BL Plassman, RB Wallace, AR Herzog, SG Heeringa, MB Ofstedal, et al. The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology. 25: 2005; 181 – 191
dc.identifier.citedreferenceRS Wilson, DR Weir, S Leurgans, DA Evans, LE Hebert, KM Langa, et al. Sources of variability in estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimer Dement (in press).
dc.identifier.citedreferenceAmerican Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM III). 1980; American Psychiatric Association: Washington, DC
dc.identifier.citedreferenceH Petrovitch, GW Ross, Q He, J Uyehara‐Lock, W Markesbery, D Davis, et al. Characterization of Japanese‐American men with a single neocortical AD lesion type. Neurobiol Aging. 29: 2008; 1448 – 1455
dc.identifier.citedreferenceR Mayeux, AM Saunders, S Shea, S Mirra, D Evans, AD Roses, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s Disease Centers Consortium on Apolipoprotein E and Alzheimer’s Disease. N Engl J Med. 338: 1998; 506 – 511, Erratum in: N Engl J Med 1998;338:1325
dc.identifier.citedreferenceJA Schneider, NT Aggarwal, L Barnes, P Boyle, DA Bennett. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 18: 2009; 691 – 701
dc.identifier.citedreferenceCL Meinert, S Tonascia. Clinical trials: design, conduct, and analysis. 1986; Oxford University Press: New York, NY
dc.identifier.citedreferenceM Albert, LA Smith, PA Scherr, JO Taylor, DA Evans, HH Funkenstein. Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer’s disease. Int J Neurosci. 57: 1991; 167 – 178
dc.identifier.citedreferenceGG Fillenbaum, CF Pieper, HJ Cohen, JC Cornoni‐Huntley, JM Guralnik. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. J Gerontol A Biol Sci Med Sci. 55: 2000; M84 – M89
dc.identifier.citedreferenceG McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 34: 1984; 939 – 944
dc.identifier.citedreferenceHC Chui, JI Victoroff, D Margolin, W Jagust, R Shankle, R Katzman, et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 42: 1992; 473 – 480
dc.identifier.citedreferenceGC Roman, TK Tatemichi, T Erkinjuntti, JL Cummings, JC Masdeu, JH Garcia, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology. 43: 1993; 250 – 260
dc.identifier.citedreferenceIG McKeith, EK Perry, RH Perry. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 53: 1999; 902 – 905
dc.identifier.citedreferenceBL Miller, C Ikonte, M Ponton, M Levy, K Boone, A Darby, et al. A study of the Lund‐Manchester research criteria for frontotemporal dementia: clinical and single‐photon emission CT correlations. Neurology. 48: 1997; 937 – 942
dc.identifier.citedreferenceRC Petersen, GE Smith, SC Waring, RJ Ivnik, EG Tangalos, E Kokmen. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56: 1999; 303 – 308
dc.identifier.citedreferenceB Winblad, K Palmer, M Kivipelto, V Jelic, L Fratiglioni, LO Wahlund, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 256: 2004; 240 – 246
dc.identifier.citedreferenceMF Elias, A Beiser, PA Wolf, R Au, RF White, RB D’Agostino. The preclinical phase of Alzheimer disease: a 22‐year prospective study of the Framingham Cohort. Arch Neurol. 57: 2000; 808 – 813
dc.identifier.citedreferenceDA Evans, HH Funkenstein, MS Albert, PA Scherr, NR Cook, MJ Chown, et al. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA. 262: 1989; 2551 – 2556
dc.identifier.citedreferenceDA Evans, DA Bennett, RS Wilson, JL Bienias, MC Morris, PA Scherr, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol. 60: 2003; 185 – 189
dc.identifier.citedreferenceRS Wilson, NT Aggarwal, LL Barnes, CF Mendes de Leon, LE Hebert, DA Evans. Cognitive decline in incident Alzheimer disease in a community population. Neurology. 74: 2010; 951 – 955
dc.identifier.citedreferencePJ Visser, F Verhey, DL Knol, P Scheltens, LO Wahlund, Y Freund‐Levi, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8: 2009; 619 – 627
dc.identifier.citedreferenceCR Jack Jr., DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9: 2010; 119 – 128
dc.identifier.citedreferenceRC Petersen. Alzheimer’s disease: progress in prediction. The Lancet Neurology. 9: 2010; 4 – 5
dc.identifier.citedreferenceRC Petersen, PS Aisen, LA Beckett, MC Donohue, AC Gamst, DJ Harvey, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 74: 2010; 201 – 209
dc.identifier.citedreferenceWJ Jagust, SM Landau, LM Shaw, JQ Trojanowski, RA Koeppe, EM Reiman, et al. Relationships between biomarkers in aging and dementia. Neurology. 73: 2009; 1193 – 1199
dc.identifier.citedreferenceLM Shaw, H Vanderstichele, M Knapik‐Czajka, CM Clark, PS Aisen, RC Petersen, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 65: 2009; 403 – 413
dc.identifier.citedreferenceGA Jicha, JE Parisi, DW Dickson, K Johnson, R Cha, RJ Ivnik, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 63: 2006; 674 – 681
dc.identifier.citedreferenceRC Petersen, RO Roberts, DS Knopman, BF Boeve, YE Geda, RJ Ivnik, et al. Mild cognitive impairment: ten years later. Arch Neurol. 66: 2009; 1447 – 1455
dc.identifier.citedreferenceC Kawas, S Gray, R Brookmeyer, J Fozard, A Zonderman. Age‐specific incidence rates of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology. 54: 2000; 2072 – 2077
dc.identifier.citedreferenceR Brookmeyer, DA Evans, LA Hebert, KM Langa, SG Heeringa, BL Plassman, et al. National estimates of the prevalence of Alzheimer’s disease in the United States. Alzheimers Dement. 7: 2011; 61 – 73
dc.identifier.citedreferenceTR Dawber, WB Kannel. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 34: 1966; 553 – 555
dc.identifier.citedreferenceME Farmer, LR White, SJ Kittner, E Kaplan, E Moes, P McNamara, et al. Neuropsychological test performance in Framingham: a descriptive study. Psychol Rep. 60: 1987; 1023 – 1040
dc.identifier.citedreferenceMF Folstein, SE Folstein, PR McHugh. “Mini‐mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12: 1975; 189 – 198
dc.identifier.citedreferenceM Feinleib, WB Kannel, RJ Garrison, PM McNamara, WP Castelli. The Framingham Offspring Study. Design and preliminary data. Prev Med. 4: 1975; 518 – 525
dc.identifier.citedreferenceDL Bachman, PA Wolf, RT Linn, JE Knoefel, JL Cobb, AJ Belanger, et al. Incidence of dementia and probable Alzheimer’s disease in a general population: the Framingham Study. Neurology. 43: 1993; 515 – 519
dc.identifier.citedreferenceDL Bachman, PA Wolf, R Linn, JE Knoefel, J Cobb, A Belanger, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 42: 1992; 115 – 119
dc.identifier.citedreferenceA Beiser, RB D’Agostino Sr., S Seshadri, LM Sullivan, PA Wolf. Computing estimates of incidence, including lifetime risk: Alzheimer’s disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med. 19: 2000; 1495 – 1522
dc.identifier.citedreferenceS Seshadri, PA Wolf, A Beiser, R Au, K McNulty, R White, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology. 49: 1997; 1498 – 1504
dc.identifier.citedreferenceS Seshadri, A Beiser, M Kelly‐Hayes, CS Kase, R Au, WB Kannel, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 37: 2006; 345 – 350
dc.identifier.citedreferenceS Seshadri, PA Wolf. Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study. Lancet Neurol. 6: 2007; 1106 – 1114
dc.identifier.citedreferenceL Berg. Clinical dementia rating (CDR). Psychopharmacol Bull. 24: 1988; 637 – 639
dc.identifier.citedreferenceAmerican Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV. 4th ed.. 1994; American Psychiatric Association: Washington, DC
dc.identifier.citedreferenceRO Roberts, YE Geda, DS Knopman, RH Cha, VS Pankratz, BF Boeve, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 30: 2008; 58 – 69
dc.identifier.citedreferenceE Kokmen, CM Beard, KP Offord, LT Kurland. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology. 39: 1989; 773 – 776
dc.identifier.citedreferenceZS Khachaturian. Diagnosis of Alzheimer’s disease: two‐decades of progress. J Alzheimers Dis. 9: 2006; 409 – 415
dc.identifier.citedreferenceSS Mirra, A Heyman, D McKeel, SM Sumi, BJ Crain, LM Brownlee, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 41: 1991; 479 – 486
dc.identifier.citedreferenceR Brookmeyer, S Gray, C Kawas. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 88: 1998; 1337 – 1342
dc.identifier.citedreferenceDS Knopman, JE Parisi, A Salviati, M Floriach‐Robert, BF Boeve, RJ Ivnik, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 62: 2003; 1087 – 1095
dc.identifier.citedreferenceDG Davis, FA Schmitt, DR Wekstein, WR Markesbery. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 58: 1999; 376 – 388
dc.identifier.citedreferenceM Gearing, SS Mirra, JC Hedreen, SM Sumi, LA Hansen, A Heyman. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology. 45: 1995; 461 – 466
dc.identifier.citedreferenceJA Schneider, Z Arvanitakis, SE Leurgans, DA Bennett. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 66: 2009; 200 – 208
dc.identifier.citedreferenceA Lim, D Tsuang, W Kukull, D Nochlin, J Leverenz, W McCormick, et al. Clinico‐neuropathological correlation of Alzheimer’s disease in a community‐based case series. J Am Geriatr Soc. 47: 1999; 564 – 569
dc.identifier.citedreferenceMD Ikonomovic, WE Klunk, EE Abrahamson, CA Mathis, JC Price, ND Tsopelas, et al. Post‐mortem correlates of in vivo PiB‐PET amyloid imaging in a typical case of Alzheimer’s disease. Brain. 131: 2008; 1630 – 1645
dc.identifier.citedreferenceWE Klunk, H Engler, A Nordberg, Y Wang, G Blomqvist, DP Holt, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound‐B. Ann Neurol. 55: 2004; 306 – 319
dc.identifier.citedreferenceA Okello, J Koivunen, P Edison, HA Archer, FE Turkheimer, K Nagren, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C‐PIB PET study. Neurology. 73: 2009; 754 – 760
dc.identifier.citedreferenceRC Petersen, RO Roberts, DS Knopman, YE Geda, RH Cha, VS Pankratz, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology. 75: 2010; 889 – 897
dc.identifier.citedreferenceM Lorenzi, M Donohue, D Paternico, C Scarpazza, S Ostrowitzki, O Blin, et al. Enrichment through biomarkers in clinical trials of Alzheimer’s drugs in patients with mild cognitive impairment. Neurobiol Aging. 31: 2010; 1443 – 1451, 1451 e1
dc.identifier.citedreferenceG Blessed, BE Tomlinson, M Roth. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 114: 1968; 797 – 811
dc.identifier.citedreferenceAmerican Psychiatric Association American Psychiatric Association Work Group to Revise DSM‐III Diagnostic and Statistical Manual of Mental Disorders: DSM‐III‐R. 3rd ed.. 1987; American Psychiatric Association: Washington, DC
dc.identifier.citedreferenceLE Hebert, PA Scherr, LA Beckett, MS Albert, DM Pilgrim, MJ Chown, et al. Age‐specific incidence of Alzheimer’s disease in a community population. JAMA. 273: 1995; 1354 – 1359
dc.identifier.citedreferenceR Katzman, M Aronson, P Fuld, C Kawas, T Brown, H Morgenstern, et al. Development of dementing illnesses in an 80‐year‐old volunteer cohort. Ann Neurol. 25: 1989; 317 – 324
dc.identifier.citedreferenceC Eisdorfer, D Cohen. Diagnostic criteria for primary neuronal degeneration of the Alzheimer’s type. J Fam Pract. 11: 1980; 553 – 557
dc.identifier.citedreferenceMM Corrada, R Brookmeyer, D Berlau, A Paganini‐Hill, CH Kawas. Prevalence of dementia after age 90: results from the 90+ study. Neurology. 71: 2008; 337 – 343
dc.identifier.citedreferenceMM Corrada, R Brookmeyer, A Paganini‐Hill, D Berlau, CH Kawas. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 67: 2010; 114 – 121
dc.identifier.citedreferenceDJ Berlau, MM Corrada, E Head, CH Kawas. APOE ɛ2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 72: 2009; 829 – 834
dc.identifier.citedreferenceHA Crystal, D Dickson, P Davies, D Masur, E Grober, RB Lipton. The relative frequency of “dementia of unknown etiology” increases with age and is nearly 50% in nonagenarians. Arch Neurol. 57: 2000; 713 – 719
dc.identifier.citedreferenceGM Savva, SB Wharton, PG Ince, G Forster, FE Matthews, C Brayne, et al. Age, neuropathology, and dementia. N Engl J Med. 360: 2009; 2302 – 2309
dc.identifier.citedreferenceR Mayeux, C Reitz, AM Brickman, MN Haan, JJ Manly, MM Glymour, et al. Operationalizing diagnostic criteria for Alzheimer’s disease and other age‐related cognitive impairment—Part 1. Alzheimers Dement. 7: 2011; 15 – 34
dc.identifier.citedreferenceBL Plassman, RJ Havlik, DC Steffens, MJ Helms, TN Newman, D Drosdick, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 55: 2000; 1158 – 1166
dc.identifier.citedreferenceJC Breitner, KA Welsh, BA Gau, WM McDonald, DC Steffens, AM Saunders, et al. Alzheimer’s disease in the National Academy of Sciences‐National Research Council Registry of Aging Twin Veterans. III. Detection of cases, longitudinal results, and observations on twin concordance. Arch Neurol. 52: 1995; 763 – 771
dc.identifier.citedreferenceJC Breitner, BW Wyse, JC Anthony, KA Welsh‐Bohmer, DC Steffens, MC Norton, et al. APOE‐epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 53: 1999; 321 – 331
dc.identifier.citedreferenceBL Plassman, DC Steffens, JR Burke, KA Welsh‐Bohmer, TN Newman, D Drosdick, et al. Duke Twins Study of Memory in Aging in the NAS‐NRC Twin Registry. Twin Res Hum Genet. 9: 2006; 950 – 957
dc.identifier.citedreferenceBL Plassman, AS Khachaturian, JJ Townsend, MJ Ball, DC Steffens, CE Leslie, et al. Comparison of clinical and neuropathologic diagnoses of Alzheimer’s disease in 3 epidemiologic samples. Alzheimers Dement. 2: 2006; 2 – 11
dc.identifier.citedreferenceF Massoud, G Devi, Y Stern, A Lawton, JE Goldman, Y Liu, et al. A clinicopathological comparison of community‐based and clinic‐based cohorts of patients with dementia. Arch Neurol. 56: 1999; 1368 – 1373
dc.identifier.citedreferenceFE Matthews, BC Stephan, IG McKeith, J Bond, C Brayne. Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. J Am Geriatr Soc. 56: 2008; 1424 – 1433
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
alzjjalz201012002.pdf
Size:
690.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.